InVitae
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 217m | 280m | 460m | 516m | 484m | 524m | 576m |
% growth | 47 % | 29 % | 65 % | 12 % | (6 %) | 8 % | 10 % |
EBITDA | (232m) | (645m) | (672m) | (564m) | (193m) | (222m) | (186m) |
% EBITDA margin | (107 %) | (231 %) | (146 %) | (109 %) | (40 %) | (42 %) | (32 %) |
Profit | (242m) | (609m) | (379m) | (3.1b) | (1.4b) | (328m) | (326m) |
% profit margin | (112 %) | (218 %) | (82 %) | (602 %) | (295 %) | (63 %) | (57 %) |
EV / revenue | 6.8x | 26.8x | 9.0x | 3.2x | 2.8x | 2.4x | 2.2x |
EV / EBITDA | -6.4x | -11.6x | -6.2x | -2.9x | -7.0x | -5.8x | -6.9x |
R&D budget | 142m | 241m | 416m | 402m | - | - | - |
R&D % of revenue | 65 % | 86 % | 90 % | 78 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$3.6m | Early VC | ||
N/A | $2.3m | Early VC | |
N/A | $29.6m | Series A | |
$40.0m | Series E | ||
$120m | Series F | ||
N/A | €102m Valuation: €516m | IPO | |
* | N/A | $44.0m | POST IPO SECONDARY |
* | N/A | $74.0m | Post IPO Equity |
* | N/A | N/A | Post IPO Equity |
* | N/A | $75.0m | Post IPO Equity |
* | N/A | $197m | Post IPO Equity |
* | N/A | $300m | Post IPO Debt |
* | N/A | $184m | Post IPO Equity |
$1.2b Valuation: $7.7b 27.5x EV/LTM Revenues -11.9x EV/LTM EBITDA | Post IPO Convertible | ||
* | N/A | N/A | Bankruptcy |
* | $239m Valuation: $239m | Acquisition | |
Total Funding | €178m |
Recent News about InVitae
EditInvitae (website: invitae.com) is a pioneering company in the field of genetic testing, aiming to integrate genetic information into everyday medical practice. The company's mission is to make genetic testing affordable and accessible, thereby improving healthcare for a broad range of patients. Invitae serves a diverse clientele, including individuals with a personal or family history of genetic conditions such as breast, ovarian, colorectal, or uterine cancer, as well as those seeking proactive health insights or reproductive health information.
Operating in the healthcare and biotechnology market, Invitae leverages advanced technology to provide comprehensive and reliable genetic tests. Their offerings include diagnostic tests for hereditary conditions, reproductive health screenings, and proactive health assessments. Additionally, Invitae runs sponsored testing programs, which provide no-cost testing for specific conditions, such as long chain fatty acid oxidation disorders.
The company's business model revolves around making genetic testing more accessible by reducing costs and simplifying the process for both clinicians and patients. Invitae generates revenue through several channels: direct payments from patients, insurance reimbursements, and sponsored testing programs. They offer a patient pre-pay option, which allows individuals to pay a flat fee of $250 for certain tests, making it easier for those without comprehensive insurance coverage to access their services.
Invitae's platform is designed to be user-friendly, enabling easy ordering of test kits, scheduling of sample pickups, and tracking of test results. By focusing on affordability and accessibility, Invitae aims to democratize genetic information, empowering patients and healthcare providers with actionable insights that can lead to better health outcomes.
Keywords: genetic testing, healthcare, biotechnology, diagnostics, reproductive health, proactive health, affordable, accessible, insurance, patient care.